BRIEF published on 11/13/2024 at 07:35, 1 year ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 1 year 1 month ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 1 month ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 1 year 1 month ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 1 year 1 month ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 1 year 1 month ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 1 year 1 month ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE published on 09/27/2024 at 11:24, 1 year 2 months ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 1 year 2 months ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
Published on 12/05/2025 at 02:35, 10 hours 39 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 14 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 9 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 14 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:00, 14 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 14 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 9 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 14 minutes ago CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 14 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 08:45, 4 hours 29 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 14 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 29 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 30 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
